Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kamada ( (KMDA) ) has issued an announcement.
Kamada Ltd. held its Annual General Meeting of Shareholders on December 11, 2024, where all proposals put forward were approved by the required majority. The meeting saw the re-election of several directors and the ratification of Kost Forer Gabbay & Kasierer as the company’s independent registered public accountants for the year ending December 31, 2024. The approvals are expected to ensure stable governance and financial oversight, reinforcing Kamada’s operational continuity and strategic objectives.
More about Kamada
Kamada Ltd. is a company based in the Science Park of Rehovot, Israel, operating within the pharmaceutical sector. It specializes in the development and production of plasma-derived protein therapeutics and focuses on providing solutions for orphan diseases, immune deficiencies, and other niche medical needs.
YTD Price Performance: -0.82%
Average Trading Volume: 36,156
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $355.2M
See more data about KMDA stock on TipRanks’ Stock Analysis page.
